达比加群用于非心脏手术后心肌损伤患者(MANAGE):一项国际随机安慰剂对照试验
MANAGE试验为国际、随机、安慰剂对照试验,纳入19个国家84家医院、年龄≥45岁、非心脏手术后35天内发生MINS的患者1754例,1:1随机接受达比加群110 mg口服每日两次或安慰剂,最长2年。主要疗效终点为主要血管复合终点(血管性死亡、非致死性心肌梗死、非出血性卒中、外周动脉血栓、截肢、症状性静脉血栓栓塞),达比加群组97/877(11%) vs 安慰剂组133/877(15%),HR 0.72(95%CI 0.55-0.93),P=0.0115。主要安全终点为致命性、主要和关键器官出血复合终点,达比加群组29/877(3%) vs 安慰剂组31/877(4%),HR 0.92(95%CI 0.55-1.53),P=0.76,无显著差异。作者认为MINS患者预后差,达比加群110 mg每日两次可能有助于降低主要血管并发症风险。
要点
- MINS患者达比加群110 mg口服每日两次 vs 安慰剂:主要血管复合终点11% vs 15%,HR 0.72(95%CI 0.55-0.93),P=0.0115。
- 主要安全复合终点(致命性、主要和关键器官出血)达比加群组3% vs 安慰剂组4%,HR 0.92(95%CI 0.55-1.53),P=0.76,无显著差异。
- 研究纳入年龄≥45岁、非心脏手术后35天内发生MINS的患者,达比加群最长用2年。
- 达比加群组46%(401/877)和安慰剂组43%(380/877)永久停用研究药物。
- 作者认为MINS患者预后差,达比加群110 mg每日两次可能帮助全球800万MINS成人降低主要血管并发症风险。
适用人群与场景
- 年龄至少45岁、接受非心脏手术、且处于MINS后35天内的患者。
- 来自19个国家84家医院。
处置流程与药物剂量
- 达比加群110 mg口服每日两次,最长2年或至试验终止。
- 不服用质子泵抑制剂的患者另行1:1随机接受奥美拉唑20 mg每日一次或安慰剂(结果另文报告)。
研究设计与关键结果
- 国际、随机、安慰剂对照试验,纳入1754例患者(达比加群组877例、安慰剂组877例),来自19个国家84家医院。
- 主要疗效终点(血管性死亡、非致死性心肌梗死、非出血性卒中、外周动脉血栓、截肢、症状性静脉血栓栓塞复合终点):达比加群组97/877(11%) vs 安慰剂组133/877(15%),HR 0.72(95%CI 0.55-0.93),P=0.0115。
- 主要安全终点(致命性、主要和关键器官出血复合终点):达比加群组29/877(3%) vs 安慰剂组31/877(4%),HR 0.92(95%CI 0.55-1.53),P=0.76。
- 研究药物永久停用:达比加群组401/877(46%) vs 安慰剂组380/877(43%)。
- 556例患者同时参与奥美拉唑部分析因随机。
证据类型、等级与局限
- 证据类型:国际、随机、安慰剂对照试验(MANAGE),按意向性治疗原则分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,MINS患者预后差,达比加群110 mg每日两次可能帮助全球800万MINS成人降低主要血管并发症风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran prevents perioperative venous thromboembolism, but whether this drug can prevent a broader range of vascular complications in patients with MINS is unknown. The MANAGE trial assessed the potential of dabigatran to prevent major vascular complications among such patients.
METHODS: In this international, randomised, placebo-controlled trial, we recruited patients from 84 hospitals in 19 countries. Eligible patients were aged at least 45 years, had undergone non-cardiac surgery, and were within 35 days of MINS. Patients were randomly assigned (1:1) to receive dabigatran 110 mg orally twice daily or matched placebo for a maximum of 2 years or until termination of the trial and, using a partial 2-by-2 factorial design, patients not taking a proton-pump inhibitor were also randomly assigned (1:1) to omeprazole 20 mg once daily, for which results will be reported elsewhere, or matched placebo to measure its effect on major upper gastrointestinal complications. Research personnel randomised patients through a central 24 h computerised randomisation system using block randomisation, stratified by centre. Patients, health-care providers, data collectors, and outcome adjudicators were masked to treatment allocation. The primary efficacy outcome was the occurrence of a major vascular complication, a composite of vascular mortality and non-fatal myocardial infarction, non-haemorrhagic stroke, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolism. The primary safety outcome was a composite of life-threatening, major, and critical organ bleeding. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01661101.
FINDINGS: Between Jan 10, 2013, and July 17, 2017, we randomly assigned 1754 patients to receive dabigatran (n=877) or placebo (n=877); 556 patients were also randomised in the omeprazole partial factorial component. Study drug was permanently discontinued in 401 (46%) of 877 patients allocated to dabigatran and 380 (43%) of 877 patients allocated to placebo. The composite primary efficacy outcome occurred in fewer patients randomised to dabigatran than placebo (97 [11%] of 877 patients assigned to dabigatran vs 133 [15%] of 877 patients assigned to placebo; hazard ratio [HR] 0·72, 95% CI 0·55-0·93; p=0·0115). The primary safety composite outcome occurred in 29 patients (3%) randomised to dabigatran and 31 patients (4%) randomised to placebo (HR 0·92, 95% CI 0·55-1·53; p=0·76).
INTERPRETATION: Among patients who had MINS, dabigatran 110 mg twice daily lowered the risk of major vascular complications, with no significant increase in major bleeding. Patients with MINS have a poor prognosis; dabigatran 110 mg twice daily has the potential to help many of the 8 million adults globally who have MINS to reduce their risk of a major vascular complication [corrected].
FUNDING: Boehringer Ingelheim and Canadian Institutes of Health Research.
参考来源
- Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018. PMID: 29900874. doi:10.1016/S0140-6736(18)30832-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。